ROS1 and non-small cell lung carcinoma: Consider performing pharmacological thromboprophylaxis with LMWH or DOAC in other patients with high risk, such as those with non-small cell lung cancer with ROS-1 or ALK rearrangement, and patients classified as high risk according to a validated RAM, who are receiving systemic therapy, without contraindications for anticoagulation and with low risk of bleeding (Grade II, B recommendation).